GLOBOMARK IP
  • home
  • what we do
    • Patent Filing in Indonesia
    • International TM Protection
    • Trademark Registration in Indonesia
    • Industrial Designs
    • Recordation of Changes
  • our team
  • blog
  • careers

​

Pharmaceutical Patent Evergreening in Indonesia: The Constitutional Court Restores Article 4(f) of the Patent Law

10/9/2026

0 Comments

 
· Marsha Aisyah      · Bertha Verdina

On 28 August 2026, the Indonesian Constitutional Court, through Decision No. 255/PUU-XXIII/2025, restored the substance of Article 4(f) of Law No. 13 of 2016 on Patents, as amended by Law No. 65 of 2024. The decision restores the statutory exclusion of certain new uses of existing and/or known products and certain new forms of existing compounds from patent protection. While the provision is not limited to the pharmaceutical sector, the decision is particularly relevant to pharmaceutical patent protection, including patents relating to second medical use and new forms of known pharmaceutical compounds.
 
Evergreening in Pharmaceutical Patents
A patent grants exclusive rights to an inventor or patent holder over an invention for a certain period of time. In the pharmaceutical field, such protection plays an important role because the development of new medicines requires extensive research and significant investment. In return, the patent system provides a period of exclusivity so that inventors or companies developing medicines can obtain economic benefits from the results of their innovations.
 
Under Law No. 13 of 2016 on Patents, a standard patent is granted for a period of 20 years from the filing date, while simple patents receive 10 years of protection. There is no mechanism to simply extend a patent after its term of protection has expired.
 
The issue subsequently known as evergreening arises through a different mechanism. Evergreening essentially refers to efforts to obtain additional patent protection for an existing product, for example through the development of formulations, changes in methods of administration, combinations of active ingredients, or new therapeutic uses. Such additional patents may allow a patent holder to maintain commercial exclusivity over the same product or a related product even when the original patent is approaching the end of, or has reached the end of, its term of protection.
 
Article 4(f) and the 2024 Amendment
Prior to the amendment through Law No. 65 of 2024, Article 4(f) of Law No. 13 of 2016 specifically excluded the following from the definition of an invention:
“discoveries in the form of:  
1. new uses for existing and/or known products; and/or
2. new forms of existing compounds that do not result in a significant increase in efficacy and have related differences in chemical structure from the compound that is already known.”
 
However, through Law No. 65 of 2024, paragraph (f) of Article 4 was deleted. As a result, these express exclusions were removed from Article 4 of the Patent Law. 
 
Constitutional Court Decision No. 255/PUU-XXIII/2025
On 28 August 2026, the Constitutional Court partially granted the petition in Case No. 255/PUU-XXIII/2025 and declared the word “dihapus” (“deleted”) in Article 4(f), as amended by Law No. 65 of 2024, to be contrary to the 1945 Constitution and to have no binding legal force, subject to the interpretation that Article 4(f) excludes the following from patent protection:
 
(i) new uses for existing and/or known products; and/or
(ii) new forms of existing compounds that do not result in a significant increase in efficacy and have related differences in chemical structure already known from the compound. 
 
The Court considered the provision important in preventing patent evergreening, particularly in the pharmaceutical sector, and in supporting access to affordable medicines and the generic pharmaceutical industry. 
 
The Court also restored the relevant Elucidation of Article 4(f) under Law No. 13 of 2016, which provides, among other things, clarification of the meaning of “existing and/or known products” and the concept of a “significant” increase in efficacy in the pharmaceutical field.
 
Implications for Pharmaceutical Patents
The decision is particularly relevant to pharmaceutical patent applications involving new therapeutic uses (second medical use), new forms of known compounds, and other developments relating to existing pharmaceutical products.
 
Importantly, the decision does not mean that all modifications of existing pharmaceutical products are unpatentable. The exclusion specifically concerns the subject matter covered by Article 4(f), while inventions falling outside those exclusions must still be assessed against the applicable patentability requirements under the Patent Law. 
 
Primary Source:
Constitutional Court Decision No. 255/PUU-XXIII/2025.
0 Comments

Your comment will be posted after it is approved.


Leave a Reply.

    IP Blog

    by globomark ip

    Provides updates, news and insights into IP issues.

    RSS Feed


    M I T R A

    Picture
    Sejak 2011, kami aktif sebagai salah satu narasumber yang khusus menjawab pertanyaan-pertanyaan di bidang HKI bagi pengunjung situs www.hukumonline.com. 
    Lihat arsip tanya jawab HKI kami di Klinik Hukumonline, di sini. 

    A R C H I V E S

    October 2026
    July 2012
    May 2012
    November 2011
    September 2010
    October 2009
    July 2009

Picture
Picture
Picture
Picture

TRADEMARK (TM)
  • TM Search
  • TM Filing & Prosecution
  • International TM Protection
  • TM Opposition & Counter-Opposition
  • Appeal to the Marks Appeal Board
  • TM Monitoring/Surveillance
  • Recordation of Changes
  • TM Renewal
  • TM License

COPYRIGHT
  • Copyright Recordation

INDUSTRIAL DESIGN (ID)
  • ID Search
  • ID Filing & Prosecution
  • International ID registration
PATENT
  • Patent Search
  • Patent Drafting
  • ​Patent Translation
  • Patent Filing & Prosecution
  • Patent Maintenance (incld. Annuity & Working Statement Submission)
  • Appeal to the Patent Appeal Board
  • Patent Opposition
  • Patent Invalidation 

LITIGATION SUPPORT
  • IP Cancellation Action
  • Patent Invalidation
  • IP Cautionary Notice
CONTACT

​Address

DBS Bank Tower Lt. 28, Ciputra World One,
Jl. Prof. Dr. Satrio Kav 3-5, 
Jakarta  12940,  INDONESIA
Telephone 
+62 (21) 2988 7918 
Email
[email protected]


Protecting Your Privacy
We have a strict privacy-of-information policy and your information
​will never be shared with anyone outside our office.
© 2003-2025 Globomark. All rights reserved. 
Legal Notice
  • home
  • what we do
    • Patent Filing in Indonesia
    • International TM Protection
    • Trademark Registration in Indonesia
    • Industrial Designs
    • Recordation of Changes
  • our team
  • blog
  • careers